Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.

Area of Science:

• Vaccinology
• Virology
• Public Health

Background:

• Inactivated poliovirus vaccine (IPV), introduced in 1955, is a cornerstone in poliomyelitis prevention.
• Despite its proven efficacy against paralytic polio, IPV's use in global eradication efforts has been limited by manufacturing complexities, cost, and perceived gaps in mucosal immunity induction compared to oral polio vaccine (OPV).

Observation:

• The Global Polio Eradication Initiative (GPEI) has focused on enhancing the scientific understanding of IPV over two decades.
• Key initiatives include expanding manufacturing, improving vaccine immunogenicity, and developing safer production methods.

Findings:

• IPV's scientific knowledge base is expanding, with ongoing research into non-infectious production methods like virus-like particles.
• Development is progressing on vaccines that induce both humoral and intestinal mucosal immunity, alongside novel administration techniques such as microneedle patches and jet injectors.

Implications:

• These advancements aim to make IPV more accessible, effective, and suitable for house-to-house administration.
• The focus is shifting from the necessity of IPV to optimizing its implementation for global polio eradication.